FDA Approves Two New Drugs to Treat Gonorrhea

In a significant milestone for public health, the U.S. Food and Drug Administration (FDA) approved two new antibiotics in late 2025 to treat gonorrhea. This development arrives just weeks after the World Health Organization (WHO) issued a stark warning regarding the global rise of antibiotic-resistant infections.

The two medications, gepotidacin and zoliflodacin, represent the first entirely new treatment options for the infection in more than thirty years. Unlike previous treatments that relied on injections, these new antibiotics are administered orally, which may simplify clinical distribution.

The Challenge of Drug Resistance

Gonorrhea remains one of the most prevalent bacterial sexually transmitted infections worldwide, with an estimated 82 million global cases annually. In the United States alone, the centres for Disease Control and Prevention (CDC) estimates 1.6 million cases each year.

The bacteria responsible for the infection has shown a persistent ability to evolve, successfully developing resistance to nearly every major class of antibiotics, including penicillins, tetracyclines and fluoroquinolones. This evolution forced clinicians to rely heavily on cephalosporins, specifically the injectable antibiotic ceftriaxone, as the final line of effective defence.

Did You Know? Nuzolvence (zoliflodacin) was developed through a partnership between the Global Antibiotic Research and Development Partnership—a nonprofit established by the WHO—and the U.S.-based Innoviva Specialty Therapeutics to address the lack of profit-driven incentive for new antibiotic research.

New Therapeutic Options

Gepotidacin, marketed as Blujepa, is taken as a course of eight pills in two doses. Clinical study data involving 628 patients indicated a 93% cure rate, comparable to the 91% rate observed in patients treated with the standard ceftriaxone and azithromycin regimen. While patients using Blujepa reported some side effects like nausea and diarrhea, these were generally described as mild.

FDA Approves New Antibiotics to Combat Rising Gonorrhea Cases

Zoliflodacin, sold as Nuzolvence, is administered as a single dose that dissolves in water. In a trial of 930 patients, 91% were cured at the one-week mark. To combat the risk of future resistance, Nuzolvence is intended exclusively for the treatment of gonorrhea, a strategic move aimed at preventing the overuse that often contributes to bacterial adaptation.

Expert Insight: Edward Hook, MD, emeritus professor of medicine at the University of Alabama, notes that the introduction of these oral antibiotics is a vital addition to care. Given that many individuals remain asymptomatic and can unknowingly transmit the infection, these new, accessible treatment options may prove critical in preventing long-term complications like infertility.

Looking Ahead

The arrival of these drugs could fundamentally shift how healthcare providers manage STI clinical protocols. Because these medications are not part of existing antibiotic classes, they may provide a durable solution for cases where traditional treatments have failed. Analysts expect that the ease of oral administration could lead to higher completion rates for treatment regimens, potentially reducing the number of untreated cases that contribute to broader public health challenges.

Frequently Asked Questions

Why are these new drugs considered a major development?
They are the first completely new antibiotic treatment options for gonorrhea approved by the FDA in over thirty years, offering alternatives to the standard injectable cephalosporins.

How do these drugs prevent further antibiotic resistance?
These medications belong to entirely new classes of antibiotics. Nuzolvence will be used specifically and exclusively for gonorrhea to prevent the overuse that drives bacterial resistance.

Are there specific side effects associated with the new treatments?
Studies for Blujepa noted side effects such as nausea and diarrhea, though these were generally reported as mild.

How do you think increased access to oral treatments might change the way we approach routine STI screenings?